Why Nektar Therapeutics (NKTR) Stock Is Up Today

NEW YORK (TheStreet) -- Nektar Therapeutics (NKTR) shares are up 9.8% to $12.13.

The rise follows an initiation of coverage with a "buy" rating and $15 price target by analysts at Jefferies Group (JEF).

The positive rating comes on speculation about the approval of the drug manufacturer's once a day opiod-induced constipation relieving pill, Naloxegol, which Jefferies believes could provide a major boost to the company's bottom line.

The FDA panel reviewing the drug is set to meet in mid-June.

Must Read: Warren Buffett's 10 Favorite Stocks

SELL NOW: If you own any of the 900 stocks that TheStreet Quant Ratings has identified as a 'Sell'...you could potentially lose EVERYTHING in the next 6-12 months. Learn more.

NKTR Chart

NKTR data by YCharts

STOCKS TO BUY: TheStreet's Stocks Under $10 has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more. 

More from Markets

Dow Sinks for Eighth Straight Session; Intel's CEO Departs -- ICYMI

Dow Sinks for Eighth Straight Session; Intel's CEO Departs -- ICYMI

Dow Logs Eighth Straight Drop as Stocks Slump

Dow Logs Eighth Straight Drop as Stocks Slump

This Is What's Hot Thursday - Stocks Slide, Intel's CEO Woes & Major Movers

This Is What's Hot Thursday - Stocks Slide, Intel's CEO Woes & Major Movers

U.S. Banks Pass Fed 'Stress Test' With Room for Dividends, Buybacks

U.S. Banks Pass Fed 'Stress Test' With Room for Dividends, Buybacks

U.S. Drillers at Mercy of Iran, Saudi Production Spat as OPEC Meeting Begins

U.S. Drillers at Mercy of Iran, Saudi Production Spat as OPEC Meeting Begins